MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/inf.0000000000003773

Медицинская библиотека · The Pediatric infectious disease journal · 2022

Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series.

Rau Cornelius, Auer-Hackenberg Lorenz, Deubzer Hedwig E, Schwabel Elisabeth, Jaros Maria, Diederichs Antonia, Lehrnbecher Thomas, Holm Mette, von Linstow Marie-Louise, Martin Luise, Dinges Sarah Svenja, Rothensteiner Maria, Siepermann Meinolf, Strenger Volker, von Both Ulrich, Teig Norbert, Brinkmann Folke, Leeb Franziska, Zeitlinger Markus, Kobbe Robin, Götzinger Florian

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Although severe COVID-19 in children is rare, those with certain pre-existing health conditions are more prone to severe disease. Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potent antiviral agents that reduce adverse clinical outcomes in adults, but are commonly not approved for use in pediatric patients.

METHODS

We retrospectively evaluated mAb treatment in children <12 years of age or <40kg with SARS-CoV-2 infection between January 1, 2021, and March 7, 2022, in 12 tertiary care centers in 3 European countries.

RESULTS

We received data from 53 patients from Austria, Denmark and Germany. Median age was 5.4 years [0-13.8, interquartile range (IQR) = 6.2], and median body weight was 20 kg (3-50.1, IQR = 13). The most frequent SARS-CoV-2 variant in this study, if known, was Omicron, followed by Delta and Alpha. Pre-existing conditions included immunodeficiency, malignancy, hematologic disease, cardiac disease, chronic lung disease, chronic liver disease, kidney disease and diabetes. Forty-two patients received sotrovimab (79%), 9 casirivimab/imdevimab (17%) and 2 bamlanivimab (4%). All but 1 patient survived. Median duration of hospital stay was 3 days (0-56, IQR = 6). Seven patients required treatment in an intensive care unit, and 5 required high-flow nasal cannula treatment. Potential side effects included neutropenia (6/53, 11%), lymphopenia (3/53, 6%), nausea or vomiting (2/53, 4%), rise of alanine transaminase (1/53, 2%) and hypotonia (1/53, 2%).

CONCLUSIONS

MAb treatment was well tolerated by children in this cohort.

Для цитирования: Rau Cornelius, Auer-Hackenberg Lorenz, Deubzer Hedwig E, Schwabel Elisabeth, Jaros Maria, Diederichs Antonia, Lehrnbecher Thomas, Holm Mette, von Linstow Marie-Louise, Martin Luise, Dinges Sarah Svenja, Rothensteiner Maria, Siepermann Meinolf, Strenger Volker, von Both Ulrich, Teig Norbert, Brinkmann Folke, Leeb Franziska, Zeitlinger Markus, Kobbe Robin, Götzinger Florian. Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series.. The Pediatric infectious disease journal. 2022. DOI: 10.1097/inf.0000000000003773.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.